Payment overview · 2025
General Payments
$43.12
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brittany Baldwin, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1043740558
Verified facts
What the public records show
CMS Open Payments records show Brittany Baldwin, D.O. received $43.12 in general payments during 2025 across 2 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 57.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuplazid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.62 | 57.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.50 | 42.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $43.12 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1094 | 109 |
| Eliquis | Apixaban | 961 | 50 |
| Gabapentin | Gabapentin | 777 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 64 |
| Omeprazole | Omeprazole | 485 | 67 |
| Lisinopril | Lisinopril | 461 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 42 |
| Sertraline Hcl | Sertraline Hcl | 300 | 39 |
| Levetiracetam | Levetiracetam | 268 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 262 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 29 |
| Metformin Hcl | Metformin Hcl | 236 | 31 |
| Carvedilol | Carvedilol | 228 | 24 |
| Mirtazapine | Mirtazapine | 227 | 24 |
| Buspirone Hcl | Buspirone Hcl | 218 | 37 |
| Furosemide | Furosemide | 216 | 27 |
| Donepezil Hcl | Donepezil Hcl | 212 | 29 |
| Allopurinol | Allopurinol | 205 | 17 |
| Jardiance | Empagliflozin | 193 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 26 |
| Trazodone Hcl | Trazodone Hcl | 185 | 29 |
| Sucralfate | Sucralfate | 175 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 22 |
| Brilinta | Ticagrelor | 171 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 28 |
| Memantine Hcl | Memantine Hcl | 154 | 19 |
| Potassium Chloride | Potassium Chloride | 154 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 20 |
| Divalproex Sodium | Divalproex Sodium | 120 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 20 |
| Pregabalin | Pregabalin | 93 | suppressed |
| Xarelto | Rivaroxaban | 93 | suppressed |
| Aripiprazole | Aripiprazole | 88 | 11 |
| Simvastatin | Simvastatin | 87 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 85 | 44 |
| Lubiprostone | Lubiprostone | 83 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 79 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 79 | 22 |
| Alprazolam | Alprazolam | 76 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 15 |
| Baclofen | Baclofen | 75 | 11 |
| Losartan Potassium | Losartan Potassium | 73 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | suppressed |
| Mupirocin | Mupirocin | 66 | 35 |
| Primidone | Primidone | 65 | suppressed |
| Finasteride | Finasteride | 64 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | suppressed |
| Prednisone | Prednisone | 62 | 12 |
| Valsartan | Valsartan | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Lorazepam | Lorazepam | 58 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Cefdinir | Cefdinir | 57 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 17 |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 53 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Sulfasalazine | Sulfasalazine | 53 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 50 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Latanoprost | Latanoprost | 47 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Silodosin | Silodosin | 42 | suppressed |
| Sotalol | Sotalol Hcl | 41 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Movantik | Naloxegol Oxalate | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 25 |
| Aptiom | Eslicarbazepine Acetate | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 17 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 34 | 21 |
| Lacosamide | Lacosamide | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Auryxia | Ferric Citrate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 22 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 16 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 14 | 11 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.12 · 2 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, NUPLAZID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error